Novuson is a leading brand in the field of surgical and trauma procedures, specializing in their Direct Therapeutic Ultrasound (DTU) technology platform. Developed by a team of experts from the University of Washington's renowned Applied Physics Laboratory, Novuson's DTU technology allows clinicians to perform surgeries more efficiently and effectively control bleeding associated with traumatic injuries. Founded by Stuart B.

Mitchell, PhD, who has over 20 years of experience in biomedical instrumentation and device design, Novuson is dedicated to improving surgical outcomes and saving lives. At Novuson, they embrace a set of core values that include teamwork, respect for individual uniqueness, openness, dedication, quality, integrity, and innovation. The executive team and board of directors comprise accomplished professionals from various backgrounds, including medical advisory, operations and finance, and program and product management.

Their wealth of expertise and experience ensures that Novuson remains at the forefront of medical device solutions. With a commitment to engineering the safer pharmacy, Novuson aims to eliminate medication waste and medical errors within the healthcare system. Their CEO and Chairman of the Board, Carla Corkern, brings more than 20 years of high-tech and supply chain management experience to the company.

Through their dedication to innovation and patient safety, Novuson continues to pioneer advancements in surgical technology, delivering high-quality products and services that improve healthcare outcomes. For more information, please visit their website or contact them directly via phone or email